• Fainareti N Zervou, Ioannis M Zacharioudakis, Jaclynn Kurpewski, and Eleftherios Mylonakis.
• Infectious Diseases Division, Rhode Island Hospital, Warren Alpert Medical School of Brown University, 593 Eddy Street, POB, 3rd Floor, Suite 328/330, Providence, RI, 02903, USA.
• Methods Mol. Biol. 2017 Jan 1; 1508: 305-319.

AbstractRapid diagnostic methods for fungal infections are long awaited and are expected to improve outcomes through early initiation of targeted antifungal therapy. T2Candida panel is a novel qualitative diagnostic platform that was recently approved by the US Food and Drug Administration (FDA) for diagnosis of candidemia with a mean time to species identification of less than 5 h. T2Candida panel is performed on the fully automated T2Dx instrument in whole blood K2EDTA specimens and is able to detect 5 Candida spp., namely Candida albicans, Candida tropicalis, Candida parapsilosis, Candida krusei, and Candida glabrata. By combining magnetic resonance with molecular diagnostics, T2Candida panel amplifies DNA and detects the amplified product by amplicon-induced agglomeration of supermagnetic particles and T2 Magnetic Resonance (T2MR) measurement. Here we describe the materials and methods needed to diagnose candidemia with the T2Candida panel.

7 keywords...

hide…